These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 5345207)

  • 1. Antiparkinsonian drugs: inhibition of dopamine uptake in the corpus striatum as a possible mechanism of action.
    Coyle JT; Snyder SH
    Science; 1969 Nov; 166(3907):899-901. PubMed ID: 5345207
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An evaluation of various antiparkinsonian agents as releasing agents and uptake inhibitors for 3H-dopamine in slices of rat neostriatum.
    Orlansky H; Heikkila RE
    Eur J Pharmacol; 1974 Dec; 29(2):284-91. PubMed ID: 4442446
    [No Abstract]   [Full Text] [Related]  

  • 3. Catecholamine uptake by synaptosomes from rat brain. Structure-activity relationships of drugs with differential effects on dopamine and norepinephrine neurons.
    Horn AS; Coyle JT; Snyder SH
    Mol Pharmacol; 1971 Jan; 7(1):66-80. PubMed ID: 5552252
    [No Abstract]   [Full Text] [Related]  

  • 4. Structure-activity relations for the inhibition of catecholamine uptake into synaptosomes from noradrenaline and dopaminergic neurones in rat brain homogenates.
    Horn AS
    Br J Pharmacol; 1973 Feb; 47(2):332-8. PubMed ID: 4722047
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Attenuation of fluctuating striatal synaptic dopamine levels in patients with Parkinson disease in response to subthalamic nucleus stimulation: a positron emission tomography study.
    Nimura T; Yamaguchi K; Ando T; Shibuya S; Oikawa T; Nakagawa A; Shirane R; Itoh M; Tominaga T
    J Neurosurg; 2005 Dec; 103(6):968-73. PubMed ID: 16381182
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of some antiparkinsonian drugs on catecholamine neurons.
    Farnebo LO; Fuxe K; Hamberger B; Ljungdahl H
    J Pharm Pharmacol; 1970 Oct; 22(10):733-7. PubMed ID: 4394777
    [No Abstract]   [Full Text] [Related]  

  • 7. Psychoactive drugs and neurotransmitters: differentiating dopamine and norepinephrine neuronal functions with drugs.
    Snyder SH; Taylor KM; Horn AS; Coyle JT
    Res Publ Assoc Res Nerv Ment Dis; 1972; 50():359-75. PubMed ID: 4341952
    [No Abstract]   [Full Text] [Related]  

  • 8. Effect of piroheptine, a new antiparkinson drug, on dopamine uptake into synaptosomes from corpus striatum of rat brain.
    Ohashi T; Akita H; Tamura T; Noda K; Honda F
    Arzneimittelforschung; 1972 Jun; 22(6):966-72. PubMed ID: 5068358
    [No Abstract]   [Full Text] [Related]  

  • 9. Studies on the mechanism of action of the antiparkinsonian drugs memantine and amantadine: no evidence for direct dopaminomimetic or antimuscarinic properties.
    Jackisch R; Link T; Neufang B; Koch R
    Arch Int Pharmacodyn Ther; 1992; 320():21-42. PubMed ID: 1284458
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Severe depletion of cocaine recognition sites associated with the dopamine transporter in Parkinson's-diseased striatum.
    Kaufman MJ; Madras BK
    Synapse; 1991 Sep; 9(1):43-9. PubMed ID: 1796351
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Uptake and binding of catecholamines. Effect of diphenylhydantoin and a new mechanism of action.
    Hadfield MG
    Arch Neurol; 1972 Jan; 26(1):78-84. PubMed ID: 4257092
    [No Abstract]   [Full Text] [Related]  

  • 12. Effect of frontal pole ablation on biogenic amine levels in the brain.
    Nielson HC
    Exp Neurol; 1966 Aug; 15(4):484-9. PubMed ID: 5911101
    [No Abstract]   [Full Text] [Related]  

  • 13. [The role of dopamine in the physiology and pathology of the basal ganglia].
    Arushanian EB
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1972; 72(4):595-603. PubMed ID: 4341763
    [No Abstract]   [Full Text] [Related]  

  • 14. Brain amine concentrations after monoamine oxidase inhibitor administration.
    Jones AB; Pare CM; Nicholson WJ; Price K; Stacey RS
    Br Med J; 1972 Jan; 1(5791):17-9. PubMed ID: 5008339
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dopamine and norepinephrine uptake by rat brain synaptosomes: relative inhibitory potencies of 1- and d-amphetamine and amantadine.
    Thornburg JE; Moore KE
    Res Commun Chem Pathol Pharmacol; 1973 Jan; 5(1):81-9. PubMed ID: 4686111
    [No Abstract]   [Full Text] [Related]  

  • 16. Usefulness of a dopamine transporter PET ligand [(18)F]beta-CFT in assessing disability in Parkinson's disease.
    Rinne JO; Ruottinen H; Bergman J; Haaparanta M; Sonninen P; Solin O
    J Neurol Neurosurg Psychiatry; 1999 Dec; 67(6):737-41. PubMed ID: 10567489
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Levodopa-induced changes in synaptic dopamine in patients with Parkinson's disease as measured by [11C]raclopride displacement and PET.
    Tedroff J; Pedersen M; Aquilonius SM; Hartvig P; Jacobsson G; Långström B
    Neurology; 1996 May; 46(5):1430-6. PubMed ID: 8628494
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dopamine action and disorders of neurotransmitter balance.
    Birkmayer W; Birkmayer JD
    Gerontology; 1987; 33(3-4):168-71. PubMed ID: 3653699
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of L-DOPA on the synthesis and excretion of tyramine.
    Boulton AA; Wu PH
    Adv Neurol; 1974; 5():119-25. PubMed ID: 4613157
    [No Abstract]   [Full Text] [Related]  

  • 20. Clinical implications of monoamine oxidase inhibition.
    Pare CM
    Adv Biochem Psychopharmacol; 1972; 5():441-4. PubMed ID: 5054212
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.